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Imaging
Acute Hypoglycemia Decreases Myocardial Blood Flow
Reserve in Patients With Type 1 Diabetes Mellitus and in
Healthy Humans
Omar Rana, MBBS, MRCP; Christopher D. Byrne, PhD, FRCPath, FRCP; David Kerr, MD, FRCP;
David V. Coppini, MD, FRCP; Soha Zouwail, MD, PhD, FRCPath; Roxy Senior, DM, MD, FRCP, FESC;
Joe Begley, MD, FRCPath; Jeremy J. Walker, PhD; Kim Greaves, BSc, MD, FRCP
Background—Hypoglycemia is associated with increased cardiovascular mortality, but the reason for this association is
poorly understood. We tested the hypothesis that the myocardial blood flow reserve (MBFR) is decreased during
hypoglycemia using myocardial contrast echocardiography in patients with type 1 diabetes mellitus (DM) and in healthy
control subjects.
Methods and Results—Twenty-eight volunteers with DM and 19 control subjects underwent hyperinsulinemic clamps with
maintained sequential hyperinsulinemic euglycemia (plasma glucose, 90 mg/dL [5.0 mmol/L]) followed by hyperin-
sulinemic hypoglycemia (plasma glucose, 50 mg/dL [2.8 mmol/L]) for 60 minutes each. Low-power real-time
myocardial contrast echocardiography was performed with flash impulse imaging using low-dose dipyridamole stress
at baseline and during hyperinsulinemic euglycemia and hyperinsulinemic hypoglycemia. In control subjects, MBFR
increased during hyperinsulinemic euglycemia by 0.57 U (22%) above baseline (B coefficient, 0.57; 95% confidence
interval, 0.38 to 0.75; P0.0001) and decreased during hyperinsulinemic hypoglycemia by 0.36 U (14%) below baseline
values (B coefficient, 0.36; 95% confidence interval, 0.50 to 0.23; P0.0001). Although MBFR was lower in
patients with DM at baseline by 0.37 U (14%; B coefficient, 0.37; 95% confidence interval, 0.55 to 0.19;
P0.0002) compared with control subjects at baseline, the subsequent changes in MBFR during hyperinsulinemic
euglycemia and hyperinsulinemic hypoglycemia in DM patients were similar to that observed in control subjects.
Finally, the presence of microvascular complications in the patients with DM was associated with a reduction in MBFR
of 0.52 U (24%; B coefficient, 0.52; 95% confidence interval, 0.70 to 0.34; P0.0001).
Conclusions—Hypoglycemia decreases MBFR in both healthy humans and patients with DM. This finding may explain
the association between hypoglycemia and increased cardiovascular mortality in susceptible individuals. (Circulation.
2011;124:1548-1556.)
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Several studies have shown that hypoglycemia is associ-ated with an increase in cardiovascular mortality
(CVM).1–6 This association has been demonstrated in people
with and without established coronary artery disease.1–3
Importantly, patients with acute coronary syndromes appear
to have worse short- and long-term outcomes if they experi-
ence hypoglycemia in the acute phase of their presentation.2–4
For example, in patients with diabetes mellitus (DM) and
acute coronary syndromes, hypoglycemia within 48 hours of
their admission was associated with a 2-fold increase in
all-cause mortality over a 2-year follow-up.2 Similarly, Pinto
et al3 showed that patients with ST-segment–elevation myo-
cardial infarction and an admission blood glucose
4.5 mmol/L had a 3-fold increased rate of adverse outcomes
(defined as 30-day mortality and myocardial infarction).
Furthermore, in the same study, patients with DM had an
18-fold increased risk of adverse cardiac outcomes. Subse-
quently, a more recent study showed that in patients after
myocardial infarction, spontaneous hypoglycemia was asso-
ciated with a 2-fold increase in in-hospital mortality.4
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Insulin, under euglycemic conditions, has important benefi-
cial effects on the vascular tone by inducing nitric oxide–
mediated vasodilatation.7 Studies on healthy humans and pa-
tients with DM show that insulin causes a marked increase in
myocardial blood flow (MBF) and MBF reserve (MBFR) during
euglycemia.8,9 In contrast, the mechanisms by which hypogly-
cemia adversely affects the cardiovascular system are unclear.
Hypoglycemia has been associated with angina and, impor-
tantly, has been shown to increase the size of a myocardial
infarct.10,11 Furthermore, low blood glucose also encourages a
hypercoagulant state resulting from an increase in plasma
concentrations of coagulation factors and by promoting platelet
aggregation.12,13
Myocardial contrast echocardiography (MCE) is an estab-
lished technique used in the noninvasive quantification of
MBFR with an accuracy similar to that of positron emission
tomography and coronary Doppler flow wire measure-
ments.14,15 MBFR is calculated as the ratio of peak MBF to
resting MBF.14 In the absence of flow-limiting coronary
artery disease, an MBFR 2.0 is indicative of underlying
endothelial dysfunction.16 Furthermore, MBFR has been
shown to be an independent predictor of CVM in diabetic and
nondiabetic patients with normal stress echocardiograms and
in patients after acute coronary syndromes.17–19
We hypothesized that hypoglycemia would decrease the
MBFR (measured by MCE) using a 1-step hyperinsulinemic
clamp technique to induce hypoglycemia in patients with type
1 DM and in healthy control subjects.
Methods
Subjects
Twenty-eight subjects with type 1 DM (group DM) participated in
the study after approval of the local research ethical committee. In
addition, 19 healthy volunteers (group C) acted as control subjects.
All volunteers underwent testing of MBF by MCE. Assessment of
MBF was undertaken with an insulin clamp at 3 stages: at baseline,
during hyperinsulinemic euglycemia (HE), and during hyperinsu-
linemic hypoglycemia (HH). During each stage, all volunteers
underwent measurement of MBF during 2 states: at rest and after
dipyridamole-induced stress.
None of the volunteers were active smokers or had a history of
hypertension, coronary artery disease, or underlying lipid disorders.
All volunteers had normal exercise stress echocardiograms. Within
the DM group, 8 volunteers had evidence of microvascular compli-
cations (see the online-only Data Supplement). All volunteers
provided written informed consent.
Hyperinsulinemic Clamps
Volunteers were admitted after an overnight fast. The overall study
scheme is shown in Figure 1A and 1B. Written instructions were
provided to avoid caffeine-containing products and alcohol for 12
hours. In the DM group, a standard sliding-scale insulin was begun
to keep glucose levels close to 90 mg/dL (5.0 mmol/L). After a 30-
to 40-minute rest period, baseline plasma glucose was determined,
and the hyperinsulinemic clamp was begun.20 Insulin was infused at
3 mU  kg1  min1 for 4 minutes, followed by 2 mU  kg1  min1
for a further 3 minutes, after which the infusion rate was maintained
at 1.5 mU  kg1  min1. Hyperinsulinemic euglycemia (90 mg/dL
[5.0 mmol/L]) was maintained for 60 minutes after an initial
30-minute stabilization period. Glucose levels were subsequently
reduced over a 30-minute period by decreasing the 20% (wt/vol)
dextrose (Baxter Healthcare, Thetford, Norfolk, UK) infusion rate, and
symptomatic hypoglycemia (50 mg/dL [2.8 mmol/L]) was induced (see
the online-only Data Supplement). The glucose concentrations were
maintained for a further 60 minutes (HH), after which insulin infusion
was terminated and normoglycemia was restored.
Myocardial Contrast Echocardiography
We performed MCE using a commercial ultrasound machine iE33
(Philips Medical Systems, Best, the Netherlands) and SonoVue
(Bracco Research SA, Geneva, Switzerland) as the contrast agent as
previously described.21 Real-time images were recorded within 3 to
4 minutes in the 3 apical views (apical 4-chamber, apical 2-chamber,
and apical 3-chamber views) with low-power settings at a mechan-
ical index of 0.1. The focus was set at the mitral valve level.
SonoVue was initially started at 60 mL/h through the left anterograde
cannula with the VueJect infusion syringe pump (BR-INF 100,
Bracco Research, SA), which gently rotates and maintains the
contrast agent in a suspension. Thereafter, the rate was set between
48 and 60 mL/h to maximize image quality with minimal attenua-
tion. Once optimized, the machine settings were held constant
throughout each participant study. Flash-impulse imaging at a high
mechanical index (1.0) was performed to achieve complete myocar-
dial bubble destruction, after which 10 end-systolic frames were
recorded digitally in each apical view. After the resting images were
acquired, dipyridamole was infused at 0.56 mg/kg over a 4-minute
period. After an interval of 2 minutes, poststress images were
recorded within 3 to 4 minutes. This entire sequence took 14 minutes
(Figure 1B). The MCE studies were performed at baseline before
insulin infusion and during HE and HH (Figure 1A). Continuous
ECG monitoring was undertaken, and blood pressure was recorded
before and after stress during each study.
Analytic Methods
Quantitative MCE analysis was performed offline with standard
commercially available software, QLab version 7.0 (Q-Laboratory,
Philips Medical Systems). Quantitative assessment of myocardial
perfusion was performed for 10 consecutive end-systolic frames after
microbubble destruction. A region of interest was placed over the
entire thickness of the myocardium, and particular care was taken to
exclude high-intensity epicardial and endocardial borders by manu-
Figure 1. A, Study design showing glucose concentrations and
timing of myocardial contrast echocardiography (MCE) at base-
line (B), hyperinsulinemic euglycemia (HE), and hyperinsulinemic
hypoglycemia (HH). B, Sequence of image acquisition during
each MCE study at baseline and during HE and HH. MCErest
indicates MCE at rest; MCEpeak, MCE after dipyridamole-
induced stress.
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ally moving the region of interest between each frame (see Figure 2).
Background-subtracted plots of peak myocardial contrast intensity
(representing myocardial blood volume A, dB) versus pulsing
intervals (representing time) were automatically constructed by
QLab software to fit the monoexponential function conventional
equation: yA (1et).14 From these plots, the slope of the
replenishment curve was determined (representing myocardial blood
velocity , dB/s). The product of A and  yielded resting MBF
(dB2/s) and postdipyridamole MBF (peak MBF, dB2/s), respectively
(Figure I in the online-only Data Supplement).14 We calculated
MBFR by the ratio of peak MBF to resting MBF.14 Furthermore,
MBFR was calculated by dividing the peak MBF by the resting MBF
of the same segment at each of the 3 time frames (baseline, HE, and
HH). The basal segments were not included in the analysis because
of contrast attenuation.22 The remaining 10 mid and apical cardiac
segments were analyzed as shown in Figure 2.22 A segment was not
included in the analysis if there was artifact, inadequate microbubble
destruction, attenuation, or a wide variation in contrast intensity to
minimize errors. The average number of analyzable segments for
baseline, HE, and HH was 6 for each. All studies were reanalyzed
blindly for intraobserver variability, and for interobserver agreement,
100 myocardial segments were randomly analyzed by another
observer (K.G.) who was blinded to the sequence of the studies. The
intraobserver and interobserver variabilities were 7.7% and 8.2%,
respectively.
Venous samples were taken at baseline and every 30 minutes
thereafter (7 samples in total) for determination of plasma
endothelin-1 (ET-1) and epinephrine levels, as well as serum
high-sensitivity C-reactive protein and insulin levels. All assays were
performed in duplicate by a single observer (S.Z.) who was blinded
to the hemodynamic and MCE data. Plasma ET-1 levels were measured
with a quantitative sandwich enzyme immunoassay (QuantiGlo ELISA,
R&D Systems, Abingdon, UK) according to the manufacturer’s
instructions. Intra-assay and interassay coefficients of variation were
3.4% and 8.9%, respectively, with a cross-reactivity of 0.02% for
all human big ETs, 9% for ET-3, and 51% for ET-2. Plasma
high-sensitivity C-reactive protein was determined with a particle-
enhanced immunoassay with an interassay coefficient of variation
10% (Roche Diagnostics, Burgess Hill, UK). Plasma epinephrine
levels were measured after extraction and acetylation by competitive
immunoassay (Labor Diagnostika Nord, Nordhorn, Germany). Both
intra-assay and interassay coefficients of variation were 15%.
Serum insulin concentrations were measured with electrochemilu-
minescence immunoassay (Roche Diagnostics, Burgess Hill, UK).
The assay shows minimal cross-reactivity with proinsulin or recom-
binant insulin analogs, and the intra-assay and interassay coefficients
of variation were 2% and 5%, respectively.
Statistical Analysis
All data are represented as meanSD except ET-1 and high-
sensitivity C-reactive protein values, which are presented as median
(interquartile range).
For MBF, , and A, the influence of measurement stage, stress
state, and the presence of DM was assessed via mixed-effects
regression modeling (to reflect the intraclass correlation resulting
from repeated measurements made on each subject). For each of
these 3 outcomes, a mixed-effects model was fitted in which the
main effects of stage, stress state, and DM (together with all of their
possible interactions) were assessed. Modeling was performed with
the MIXED procedure in SAS software (version 9.2). Interpretation
of these models is described in the online-only Data Supplement.
In addition to yielding regression parameter estimates, the models
were used to estimate mean values for each combination of effects
(via the LSMEANS option in the MIXED procedure) and to test for
selected differences in these means. With 12 effects combinations
(ie, 3 stages2 stress states2 diabetes states [present/absent]), the
maximum number of possible between-group differences was 66. It
was fully recognized that formal testing of between-group differ-
ences under these conditions was justified only when there was some
a priori reason to anticipate the presence of an effect of interest and
under the strict understanding that the primary purpose of such
testing was the generation of hypotheses for future research rather
Figure 2. Model used for quantitative analysis of myocardial segments. A, Apical 4 chamber; B, apical 2 chamber; C, apical 3
chamber.
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than the drawing of substantive inferences. For further detailed
explanation, see the online-only Data Supplement.
For the main outcome (MBFR), the concept of stress state was not
applicable. Consequently, this outcome was investigated via a further
mixed-effects regression model in which MBFR was predicted by the
main effects of measurement stage and of DM together with that of their
interaction, by age, and by the subject’s systolic blood pressure.
Results
Subject Characteristics
The baseline characteristics of the 19 healthy volunteers (group
C) and 28 volunteers with DM are summarized in Table 1.
Hemodynamic Data
Throughout the clamp, resting heart rate, resting systolic
blood pressure, resting diastolic blood pressure, and resting
rate-pressure product were similar in groups C and DM
(Table I in the online-only Data Supplement).
Myocardial Contrast
Echocardiography–Derived Measurements
Myocardial Blood Volume
Mean myocardial blood volumes and 95% confidence inter-
vals (95% CIs) at rest (Ar) and during dipyridamole-induced
stress (Ad) are shown at baseline and during HE and HH in
Table 2. Table 3 shows the mixed-effect regression modeling
Table 1. Baseline Characteristics of Subjects
Variable
Group
DM (n28)
Group
C (n19) P
Age, y 38.79 31.88 0.013
Men, n (%) 22 (79) 11 (58) 0.13
BMI, kg/m2 25.73.5 24.92.6 0.39
SBP, mm Hg 12513 11510 0.007
DBP, mm Hg 777 737 0.05
Heart rate, bpm 7814 7916 0.71
Fasting glucose, mmol/L 10.33.9 4.90.3 0.0001
Duration of diabetes
mellitus, y
19.212
Glycosylated hemoglobin
HbA1c, %
8.91.5
Albumin/creatinine ratio,
mg  mmol1  L1
4.39.4
VPT score 8.05.6
TC, mmol/L* 4.80.9 4.30.7 0.03
LDL-C, mmol/L* 2.50.8 2.10.9 0.10
HDL-C, mmol/L* 1.80.7 1.50.3 0.10
TG, mmol/L† 1.20.7 1.31.2 0.81
DM, type 1 diabetes mellitus; C, control; BMI, body mass index; SBP, systolic
blood pressure; DBP, diastolic blood pressure; VPT, vibration perception
threshold; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol;
HDL-C, high-density lipoprotein cholesterol; and TG, triglycerides. Data are
presented as meanSD.
*To convert mmol/L to mg/dL, multiply by 38.7.
†To convert mmol/L to mg/dL, multiply by 88.6.
Table 2. Myocardial Blood Volume (A) at Rest and After Dipyridamole-Induced Stress at
Baseline and During Hyperinsulinemic Euglycemia and Hyperinsulinemic Hypoglycemia
Stage
State
DM C
Rest (Ar), dB Peak (Ad), dB Rest (Ar), dB Peak (Ad), dB
Baseline 20.0 (19.2–20.8) 22.4 (21.6–23.1) 19.3 (18.4–20.2) 22.0 (21.1–23.0)
HE 20.2 (19.3–21.1) 22.7 (21.9–23.5) 20.4 (19.4–21.5) 23.9 (22.9–24.8)
HH 21.0 (20.2–21.9) 23.9 (23.1–24.7) 21.7 (20.7–22.7) 23.0 (22.1–24.0)
Stage is baseline, hyperinsulinemic euglycemia (HE), or hyperinsulinemic hypoglycemia (HH). State is resting
(resting blood volumeAr) or during dipyridamole stress (peakAd). Values are means (95% confidence intervals).
Table 3. Mixed-Effect Regression Model Showing the Effect
of Stage (Baseline, Hyperinsulinemic Euglycemia, and
Hyperinsulinemic Hypoglycemia), State (Resting and
Dipyridamole-Induced Stress [After Stress]), and Diabetes
Mellitus on Myocardial Blood Volume (A)
Variable Estimate 95% CI P
Measurement stage
Baseline 19.3 18.4–20.2 0.0001
Euglycemia 20.4 19.4–21.5 0.0001
Hypoglycemia 21.7 20.7–22.7 0.0001
State (poststress vs rest) 2.7 1.5–3.9 0.0001
Interaction (stage with state)
Euglycemia and poststress 0.7 0.5–1.9 0.25
Hypoglycemia and poststress 1.4 2.9–0.1 0.068
Presence of diabetes mellitus
(yes vs no)
0.7 0.5–1.9 0.25
Interaction (stage with diabetes
mellitus)
Euglycemia and diabetes
mellitus present
0.9 2.5–0.6 0.22
Hypoglycemia and diabetes
mellitus present
1.4 2.9–0.1 0.075
Interaction (state with diabetes
mellitus)
Poststress and diabetes
mellitus present
0.4 1.9–1.2 0.65
Interaction (stage with state
with diabetes mellitus)
Euglycemia, poststress,
diabetes mellitus present
0.5 2.1–1.0 0.49
Hypoglycemia, poststress,
diabetes mellitus present
1.9 0.1–3.8 0.056
CI indicates confidence interval.
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testing the effect of stage, state, DM, and their interactions on
Ar and Ad.
There was a significant increase in Ad in group C at baseline
by 2.7 dB (P0.0001), as shown in Table 3. In addition, there
was marginal evidence that Ad was decreased during HH by 1.4
dB compared with baseline (P0.068). Furthermore, the pres-
ence of DM did not affect either Ar or Ad at the baseline stage
(P0.25 and P0.65, respectively). However, there was a
suggestion that Ad was increased in group DM during HH
compared with group C by 1.9 dB (P0.056).
Myocardial Blood Velocity
Mean myocardial blood velocities and 95% CIs at rest (r)
and during dipyridamole-induced stress (d) are shown at
baseline and during HE and HH in Table 4. Table 5 shows the
mixed effect regression modeling testing the effect of stage,
state, DM and their interactions on r and d.
There was a significant increase in d in group C at baseline
by 1.08 dB/s (P0.0001), as shown in Table 5. During HE, d
was further increased in group C compared with baseline values
by 0.37 dB/s (P0.0001). However, during HH, d declined and
was not different from baseline stress values (P0.28). In group
DM, r was significantly elevated compared with group C at
baseline by 0.11 dB/s (P0.035). Importantly, at baseline, d
was significantly decreased in group DM compared with group
C by 0.27 dB/s (P0.005).
In group DM, during HE and HH, a similar effect on d
was observed compared with group C with no significant
differences between the 2 groups at each stage.
Myocardial Blood Flow
Mean MBFs and 95% CIs at rest (resting MBF) and during
dipyridamole-induced stress (peak MBF) are shown at base-
line and during HE and HH in Table 6. Table 7 shows the
mixed-effect regression modeling testing the effect of stage,
state, DM, and their interactions on MBF.
In group C, peak MBF was significantly increased com-
pared with resting MBF at baseline by 26.5 dB2/s (P0.0001)
as shown in Table 7. During HE, peak MBF was further
increased in group C above baseline peak values by 11.6
dB2/s (P0.0001). However, during HH, peak MBF declined
and was not significantly different from baseline peak MBF
values (P0.20).
The resting MBF was significantly higher in group DM
compared with group C at baseline by 2.6 dB2/s (P0.015).
There was no significant difference in the resting MBF values
between the 2 groups at HE or HH. In group DM, peak MBF
was significantly decreased compared with group C at base-
line by 6.0 dB2/s (P0.006). In group DM, during HE and
HH, a similar effect on peak MBF was observed compared
with group C with no significant differences between the 2
groups at each stage.
Myocardial Blood Flow Reserve
We tested the effect of measurement stage, age, presence of
DM, and systolic blood pressure on MBFR using regression
modeling (Table 8 and Figure 3). In Table 8, the intercept of
Table 4. Myocardial Blood Velocity () at Rest and After Dipyridamole-Induced Stress at
Baseline and During Hyperinsulinemic Euglycemia and Hyperinsulinemic Hypoglycemia
Stage
State
DM C
Rest (r), dB/s Peak (d), dB/s Rest (r), dB/s Peak (d), dB/s
Baseline 1.03 (0.96–1.09) 1.84 (1.70–1.98) 0.92 (0.84–1.00) 2.00 (1.83–2.17)
HE 1.11 (1.05–1.17) 2.37 (2.22–2.51) 0.96 (0.88–1.03) 2.41 (2.23–2.58)
HH 1.18 (1.12–1.24) 1.85 (1.74–1.97) 1.04 (0.96–1.11) 2.03 (1.89–2.17)
Stage is baseline, hyperinsulinemic euglycemia (HE), or hyperinsulinemic hypoglycemia (HH). State is resting
(resting blood velocityr) or during dipyridamole stress (peakd). Values are means (95% confidence intervals).
Table 5. Mixed-Effect Regression Model Showing the Effect
of Measurement Stage (at Baseline, During Hyperinsulinemic
Euglycemia, and During Hyperinsulinemic Hypoglycemia),
Presence of Diabetes Mellitus, and Stress State (Rest Versus
After Dipyridamole-Induced Stress) on Myocardial Blood
Velocity ()
Variable Estimate 95% CI P
Measurement stage
Baseline 0.92 0.84–1.00 0.0001
Euglycemia 0.96 0.88–1.03 0.0001
Hypoglycemia 1.04 0.96–1.11 0.0001
State (after stress vs rest) 1.08 0.94–1.22 0.0001
Interaction (stage with state)
Euglycemia and poststress 0.37 0.25–0.49 0.0001
Hypoglycemia and poststress 0.08 0.23–0.07 0.28
Presence of diabetes mellitus
(yes vs no)
0.11 0.01–0.21 0.035
Interaction (stage with diabetes
mellitus)
Euglycemia and diabetes
mellitus present
0.04 0.05–0.14 0.36
Hypoglycemia and diabetes
mellitus present
0.03 0.05–0.12 0.46
Interaction (state with diabetes
mellitus)
Poststress and diabetes
mellitus present
0.27 0.45–0.08 0.005
Interaction (stage with state
with diabetes mellitus)
Euglycemia, poststress,
diabetes mellitus present
0.07 0.08–0.23 0.35
Hypoglycemia, poststress,
diabetes mellitus present
0.05 0.25–0.14 0.58
CI indicates confidence interval.
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the mixed model, the B coefficient, was 3.16 (95% CI, 2.47
to 3.85) with baseline used as a reference point. In group C,
MBFR increased during HE by 0.57 U (2.60.3 to 3.10.5;
P0.0001) (22%) above baseline and decreased during HH
by 0.36 U (2.60.3 to 2.20.2; P0.0001) (14%) below
baseline values. Importantly, at baseline, MBFR was signif-
icantly lower in group DM compared with group C by 0.37 U
(2.60.3 versus 2.10.3; P0.0002). In group DM during
HE (2.50.5), a similar effect on MBFR was observed
compared with group C; however, there was a suggestion that
in group DM, there was a smaller decrease in MBFR during
HH (1.90.4), compared with the decrease in MBFR ob-
served in group C (P0.05). Although there was a highly
significant (P0.003) and independent negative effect of age
on MBFR, the B coefficient (0.01) shows that the magni-
tude of this effect for each year of age was small. Finally,
there was no independent effect of systolic blood pressure on
MBFR.
Effect of Microvascular Complications on Myocardial
Blood Flow Reserve
The mixed-model method was applied to explore whether the
presence of microvascular complications in people with DM
was predictive of a decreased MBFR. A mixed model was
fitted (using data for subjects with DM only) in which MBFR
was predicted by stage, the presence of microvascular com-
plications, and a term representing the stage/complications
interaction. This mixed model (Table II in the online-only
Data Supplement) indicated that the presence of microvascu-
lar complications in people with DM was associated with a
reduction in MBFR of 0.52 U (B coefficient, 0.52; 95% CI,
0.70 to 0.34; P0.0001). There was no significant
interaction of complications with the stage of measurement
(ie, baseline, HE, or HH).
Table 6. Myocardial Blood Flow at Rest and After Dipyridamole-Induced Stress at Baseline
and During Hyperinsulinemic Euglycemia and Hyperinsulinemic Hypoglycemia
Stages
State
DM C
Rest MBF, dB2/s Peak MBF, dB2/s Rest MBF, dB2/s Peak MBF, dB2/s
Baseline 20.4 (19.0–21.7) 40.9 (37.5–44.4) 17.7 (16.1–19.3) 44.2 (40.0–48.5)
HE 22.2 (20.6–23.8) 53.5 (49.3–57.6) 19.3 (17.3–21.2) 57.4 (52.4–62.4)
HH 24.5 (23.0–26.0) 44.4 (41.5–47.3) 22.2 (20.4–24.0) 46.7 (43.2–50.2)
Stage is baseline, hyperinsulinemic euglycemia (HE), or hyperinsulinemic hypoglycemia (HH). State is resting
myocardial blood flow or during dipyridamole stress (myocardial blood flow MBF). Values are means (95% confidence
intervals).
Table 7. Mixed-Effect Regression Model Showing the Effect
of Measurement Stage (at Baseline, During Hyperinsulinemic
Euglycemia, and During Hyperinsulinemic Hypoglycemia),
Presence of Diabetes Mellitus, and Stress State (Rest Versus
After Dipyridamole-Induced Stress) on Myocardial Blood Flow
Variable Estimate 95% CI P
Measurement stage
Baseline 17.7 16.1–19.3 0.0001
Euglycemia 19.3 17.3–21.2 0.0001
Hypoglycemia 22.2 20.4–24.0 0.0001
State (poststress vs rest) 26.5 23.3–29.7 0.0001
Interaction (stage with state)
Euglycemia and poststress 11.6 8.9–14.4 0.0001
Hypoglycemia and poststress 2.0 5.1–1.1 0.20
Presence of diabetes mellitus
(yes vs no)
2.6 0.5–4.7 0.015
Interaction (stage with diabetes
mellitus)
Euglycemia and diabetes
mellitus present
0.3 2.1–2.6 0.83
Hypoglycemia and diabetes
mellitus present
0.4 2.4–1.6 0.71
Interaction (state with diabetes
mellitus)
Poststress and diabetes
mellitus present
6.0 10.1–1.8 0.006
Interaction (stage with state
with diabetes mellitus)
Euglycemia, poststress,
diabetes mellitus present
0.9 4.4–2.6 0.60
Hypoglycemia, poststress,
diabetes mellitus present
1.3 2.7–5.3 0.51
CI indicates confidence interval.
Table 8. Effect of Measurement Stage, Age, Presence of
Diabetes Mellitus, and Systolic Blood Pressure on Myocardial
Blood Flow Reserve
Variable B Coefficient 95% CI P
Intercept 3.16 2.47–3.85 0.0001
Measurement stage
Euglycemia vs baseline 0.57 0.38–0.75 0.0001
Hypoglycemia vs
baseline
0.36 0.50–0.23 0.0001
Age (1 y) 0.01 0.02–0.00 0.003
Presence of diabetes
mellitus
0.37 0.55–0.19 0.0002
Interaction (stage with
diabetes mellitus)
Euglycemia and diabetes
mellitus present
0.14 0.38–0.09 0.24
Hypoglycemia and
diabetes mellitus present
0.17 0.00–0.35 0.05
Systolic blood pressure 0.00 0.01–0.00 0.56
CI indicates confidence interval.
Rana et al Hypoglycemia and Myocardial Blood Flow Reserve 1553
 at SOUTHAMPTON GENERAL HOSPITAL on October 7, 2011http://circ.ahajournals.org/Downloaded from 
Changes in Concentrations of Endothelin-1,
High-Sensitivity C-Reactive Protein, Epinephrine, and
Serum Insulin During the Hyperinsulinemic Clamp
To explore further the explanation for the decrease in MBFR
during HH, we measured plasma ET-1 (as a potent vasocon-
strictor) and serum high-sensitivity C-reactive protein (as a
nonspecific marker of inflammation; Table III in the online-
only Data Supplement). Plasma ET-1 concentrations at base-
line were 0.19 pg/mL in control subjects and 1.44 pg/mL in
the group with DM (P0.0001). In the group with DM, ET-1
remained markedly increased throughout the whole clamp,
and there was a suggestion that ET-1 levels increased toward
the end of the HH clamp in control subjects. Serum high-
sensitivity C-reactive protein concentrations were not differ-
ent between the 2 groups and did not change during the study.
We also measured serum insulin levels (in view of the
hyperinsulinemic clamp) and plasma epinephrine levels (to
assess the counterregulatory response to hypoglycemia) in all
individuals (Table III in the online-only Data Supplement).
Serum insulin concentrations at baseline were 4323 pmol/L
in control subjects and 208.3207 pmol/L in the group with
DM. The plasma epinephrine levels were similar between the
2 groups at all stages.
Discussion
We have shown for the first time that insulin-induced
hypoglycemia (HH) decreases the MBFR in both patients
with type 1 DM and healthy subjects. We have demonstrated
that in healthy controls during HE, insulin induced a marked
increase in peak MBF and MBFR, whereas hypoglycemia led
to a decline in peak MBF and a decrease in MBFR. Impor-
tantly, patients with type 1 DM behaved in a manner similar
to the healthy control subjects (Figure 3) in the presence of
HE and HH, although the presence of DM was associated
with a more marked reduction in MBFR at baseline. The
reduction in peak MBF during HH appeared to be due to a
decrease in myocardial blood velocity rather than blood
volume. We have also shown that the presence of microvas-
cular complications is associated with a decrease in MBFR in
patients with type 1 DM. Therefore, the overall effect of
hypoglycemia during HH is to suppress peak MBF, thereby
mitigating the vasodilatory action of hyperinsulinemia that
occurs during physiological glucose concentrations.
A significant amount of evidence has associated hypogly-
cemia with increased CVM.1–3,6,23,24 In a study including
40 069 patients, fasting hypoglycemia was independently
associated with a 3-fold increased risk in CVM after a mean
follow-up of 8 years.1 Pinto et al3 observed that after
ST-segment–elevation myocardial infarction, patients with a
Thrombolysis in Myocardial Infarction risk score 4 and
concomitant hypoglycemia had a 11-fold increased risk of
death within 30 days compared with those with normal
glucose levels. Furthermore, another study including patients
with established coronary artery disease showed that fasting
hypoglycemia was associated with a 2-fold increase in
all-cause mortality.23 A subsequent study observed a 16%
increase in the relative risk of CVM in the group receiving
insulin therapy on admission to intensive care.6 Although this
finding was unexplained, there was a 13-fold increased
prevalence of severe hypoglycemia in the patients on insulin
therapy compared with patients receiving conventional ther-
apy. More recently, another study has demonstrated that
fasting hypoglycemia was associated with a 33% increase in
3-year mortality rates in a cohort of 1854 elderly patients after
an acute myocardial infarction.24 This negative impact on
survival was more pronounced in the subgroups with DM and
those requiring coronary artery bypass grafting with a 2- and
3-fold increase in 3-year mortality rates, respectively. This
evidence suggests that hypoglycemia is associated with short-
and long-term adverse outcomes; however, the pathophysio-
logical mechanisms are still ill defined and may vary.
Over the past few decades, several anecdotal case reports
have associated hypoglycemia with episodes of angina and
myocardial infarction.25–27 Although a direct causal link has
not been established, animal studies have demonstrated that
hypoglycemia can increase myocardial infarct size by 40%.11
Furthermore, in patients with DM and coexisting coronary artery
disease, hypoglycemia was associated with a third of all episodes
of angina and corresponding ischemic ECG changes.10
The endothelium is a highly biologically active single cell
layer responsible for the release of several substances, the most
important of which are nitric oxide and ET-1.28,29 A 21–amino
acid peptide, ET-1 is the most potent vasoconstrictor but is
identified in humans with a plasma half-life of 4 to 7 min-
utes.30,31 It induces its predominant vasoconstrictive effect by
acting on receptors located on vascular smooth muscle cells and
fibroblasts. This reduces nitric oxide bioavailability by either
decreasing its production (caveolin-1–mediated inhibition of
endothelial nitric oxide synthase activity) or increasing its
degradation (via formation of oxygen radicals).32 One recent
study demonstrated that direct infusion of ET-1 into the coronary
sinus of 6 humans decreased the coronary blood flow in a
dose-related manner by up to 25%.33 In addition, ET-1 levels
have been shown to be the strongest predictor of no reflow after
primary angioplasty.34 Several disease states have been shown to
be associated with endothelial dysfunction (an imbalance be-
tween the bioavailability of nitric oxide and ET-1). Examples
include atherosclerosis, pulmonary arterial hypertension, DM,
and myocardial ischemia.29,34–36
Figure 3. Myocardial blood flow reserve (MBFR) at baseline and
during hyperinsulinemic euglycemia (HE) and hyperinsulinemic
hypoglycemia (HH). F Indicates healthy control subjects; , type
1 diabetes mellitus patients (meansSD).
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Acute hypoglycemia has also been shown to increase ET-1
concentrations.37 Wright and coworkers37 demonstrated that
ET-1 levels in patients with type 1 DM rose by almost 70%
above baseline values 1 hour after insulin-induced hypogly-
cemia. In our study, although baseline ET-1 levels were
7-fold higher in the DM group compared with control
subjects, the effect of HH versus HE on ET-1 is uncertain. We
suggest that further work is needed specifically to elucidate
the effects of more prolonged periods of hypoglycemia on
ET-1 expression.
It is also plausible that other effects of hypoglycemia may
have a deleterious impact on MBFR besides increases in ET-1.
Hypoglycemia induces a hypercoagulant state in humans via
increased platelet aggregation and changes in plasma concentra-
tions of coagulation factors.12,13,38,39 For example, it has been
shown that factor VIII was increased 2-fold after 30 minutes of
hypoglycemia.13 Hypoglycemia may also be responsible for
initiating an inflammatory response. In 1 study, hypoglycemia
was associated with a 3-fold increase in the neutrophil count and
an elevation in neutrophil elastase, a potent proteolytic en-
zyme.39 Long-QT syndrome is well recognized as being associ-
ated with an increased risk of sudden cardiac death.40 More
worryingly, acute hypoglycemia has been demonstrated to pro-
duce prolongation of the corrected QT interval by up to 35% in
patients with type 1 DM, with values reaching 550 millisec-
onds.41,42 Interestingly, this change seems to be attributed pre-
dominantly to a surge in catecholamine levels and is independent
of electrolyte imbalance.43 Finally, prolonged hypoglycemia can
have a detrimental effect on cardiac metabolism because of the
inability of the heart to use glucose, the preferred substrate
instead of fatty acids (during acute myocardial ischemia), after
exhaustion of myocardial glycogen reserves.44
In light of our findings, it is plausible to suggest that
hypoglycemia, by causing a decrease in MBFR, may increase
the risk of CVM in susceptible individuals.
Limitations
Although dipyridamole was used 3 times in succession with
our study protocol (Figure 1A and 1B), we consider that the
repeated use of dipyridamole was unlikely to artifactually
influence our results (see the online-only Data Supplement).
We did not calculate absolute myocardial perfusion values
because all settings and infusion parameters, once optimized
at the start of each patient study, were kept constant for the
rest of that individual procedure. We deliberately did not
randomize the sequence of HE and HH because this allowed
individuals to act as their own controls, permitting constant
insulin levels, contrast infusion rates, and ultrasound machine
settings.
Conclusions
This study has shown that insulin-induced hypoglycemia is
associated with a decrease in MBFR in healthy control
subjects as a result of a reduction in peak MBF and that
patients with type 1 DM behave in a similar manner. In
contrast, insulin infusion at normal plasma glucose concen-
trations is associated with an increase in MBFR caused by an
increase in peak MBF. Exploratory analyses suggest that the
presence of DM and microvascular complications are inde-
pendently associated with MBFR during HH. We speculate
from our results that alterations in MBFR may explain the
observed association between hypoglycemia and increased
CVM in susceptible individuals.
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CLINICAL PERSPECTIVE
Hypoglycemia is a common problem that occurs in almost 20% of patients receiving intensive insulin therapy in hospital.
Several studies have recently shown that hypoglycemia is associated with an increase in cardiovascular mortality. This
association has been demonstrated in people with and without established coronary artery disease. Importantly, patients
with acute coronary syndromes appear to have worse short- and long-term outcomes if they experience hypoglycemia in
the acute phase of their presentation. The pathophysiological mechanism responsible for this association is not known. This
present study examined the effects of hypoglycemia on myocardial blood flow (MBF) reserve using myocardial contrast
echocardiography in subjects with type 1 diabetes mellitus and healthy control subjects. With the use of a 1-step
hyperinsulinemic clamp technique, insulin-induced hypoglycemia decreased the MBF reserve in both patients with type 1
diabetes mellitus and healthy subjects. Furthermore, during hyperinsulinemic euglycemia, insulin induced a marked
increase in peak MBF and MBF reserve, whereas hypoglycemia led to an increase in resting MBF and a decrease in peak
MBF, thereby decreasing the MBF reserve overall. This effect was observed in both healthy individuals and patients with
type 1 diabetes mellitus. We speculate from our results that alterations in MBF reserve may provide an explanation for the
observed association between hypoglycemia and increased cardiovascular mortality in susceptible individuals.
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Methods 
Subjects 
Microvascular  complications  (retinopathy,  neuropathy  and  nephropathy)  were  defined  
by  the  presence  of  pre-  or  proliferative  diabetic  retinopathy,  on  clinical  examination  
and  a  vibration  perception  threshold  score  of  >12  (measured  on  the  Great  Hallux  
using  a  Bio-thesiometer  [Biomedical  Instrument,  Newbury,  Ohio,  USA]),1  and  an  
albumin/creatinine  ratio  of  >2.5  mg.mmol-1.L-1  for  men  and  >3.5  mg.mmol-1.L-1  for  
women.2  Five  patients  with  type  1  DM  and  microvascular  complications  who  were  
taking  an  angiotensin  converting  enzyme  inhibitor  and  a  statin  were  instructed  not  to  
take  their  medications  48  hours  prior  to  the  study  day  to  rule  out  any  acute  effects  
of  medication  on  myocardial  perfusion.3  
 
Hyperinsulinemic Clamps 
Two  anterograde  and  one  retrograde  cannulae  were  sited  after  application  of  a  local  
anaesthetic  cream  (Ametop  gel  4.0%  w/w,  Smith  and  Nephew,  UK)  to  minimise  
discomfort.  The  anterograde  cannulae  were  inserted  into  the  antecubital  fossa  on  either  
side.  The  right  anterograde  cannula  was  used  for  insulin  (Actrapid;  Novo Nordisk,  
Copenhagen,  Denmark)  and  20%  dextrose  infusions.  A  retrograde  cannula  was  inserted  
into  the  dorsum  of  the  right  hand  and  was  kept  patent  with  a  slow  infusion  of  0.9%  
(w/v)  saline  to  which  1000  units  of  heparin  were  added.  This  hand  was  placed  in  a  
heated  box  (55-60ºC)  to  obtain arterialized  samples.4 All  studies  were  performed  in  a  
quiet  and  comfortable  room  (22-25ºC)  with  the  volunteers  resting  on  a  couch  in  a  
semi-reclined position. Arterialised glucose  sampling  was  performed  every  3-5 minutes  
and  the  20%  dextrose  infusion  was  adjusted  accordingly.  Plasma   glucose was 
determined using  a  glucose  oxidase  method  (YSI 2300  STAT  Plus,  Yellow  Springs,  
OH,  USA).5   
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Volunteers  were  asked  to  report  any  symptoms  that  could  be  attributed  to  
hypoglycemia  which  included  general  symptoms  (dry  mouth,  headache,  and  weakness),  
autonomic  symptoms  (palpitations,  trembling,  tingling,  sweating  and  feeling  hungry)  
and  neuroglycopenic  symptoms  (poor  concentration,  dizziness  and  blurred  vision).  All  
volunteers  were  provided  with  meals  and  observed  for  1-hour  at  the  end  of  which  
plasma  glucose  was  rechecked  before  allowing  them  home. 
 
Plasma glucose measurements 
The  inter-assay  coefficient  of  variation  (CV)  was  <2%  while  the  calibration  of  the  
analyzer  was  checked  at  30-minute intervals  with  a  glucose  standard  (10  mmol.L-1). 
Volunteers  were  not  informed  of  their  glucose  levels  during  the  study. 
 
Potential  additional  limitations 
Although  dipyridamole  was  used  three  times  in  succession  with  our  study  protocol  
(Figure  1a  and  b),  we  consider  that  the  repeated  use  of  dipyridamole  was  unlikely  to  
artefactually  influence  our  results. Dipyridamole  has  a  short  half-life  of  8-12  minutes  
and  the  time  period  between  each  dipyridamole  infusion  in  our  study  was  76  minutes.  
Furthermore, dipyridamole-induced  changes  in  left ventricular  ejection  fraction,  end-
systolic  volume,  heart  rate  and  diastolic  blood  pressure  have  previously  been  shown  
to  return  to  baseline  after  a  60-minute  period  using  a  much  higher-dose  (0.76  mg.kg-
1)  protocol.6 
 Finally,  the  effects  of  administering  dipyridamole  three  times  in  succession  was  
tested  in  a  healthy  individual  over  the  same  time-course  and  there  was  no  change  in  
MBF,  MBFR  or  other  hemodynamic  parameters.  We  did  not  calculate  absolute  
myocardial  perfusion  values.  This  was  because  all  settings  and  infusion  parameters,  
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once  optimised  at  the  start  of  each  patient  study,  were  kept  constant  for  the  rest  of  
that  individual  procedure. Furthermore,  we  achieved  homogenous  opacification  of  the  
left  ventricular  blood  pool  and  the  signal  intensity  received  was  consistently  between  
34-36  dB.  Calculation  of  absolute  myocardial  blood  flows  to  take  into  account  
regional  blood  flow  variations  that  occur  within  individuals  would  have  introduced  an  
additional  potential  source  of  error. 
 
Explanation  of  terms  used  in  Tables  2b,  3b  and  4b  in  the  main  manuscript  
 
Tables  2b,  3b  and  4b  in  the  main  text  of  the  paper  present  parameter  estimates  from   
mixed  effects  regression  models  in  which  the  outcome  of  interest  (respectively:  
myocardial  blood  volume,  myocardial  blood  velocity  and  myocardial  blood  flow)  is  
predicted  by  the  main  effects  of 
i. measurement  stage  (baseline,  during  hyperinsulinemic  euglycemia  and during  
hyperinsulinemic  hypoglycemia) 
ii. stress  state  (at  rest  and  post  dipyridamole-induced  stress) 
iii. diabetes  status  (controls  vs.  patients  with  diabetes) 
and  by  all  of  their  possible  interactions:  (i)  with  (ii);  (i)  with  (iii);  (ii)  with  (iii);  and  
the  single  three-way  interaction  (i)  with  (ii)  with  (iii).  Models  were fitted  using  the  
MIXED  procedure  in  SAS  software  version  9.2.  Interpretation  of  the  results  presented  
in  these  Tables  is  now  described. 
 
MEASUREMENT  STAGE  is  the  estimated  mean  value  of  the  outcome  for  control  
subjects,  in  the  rest  state,  observed  at  each  of  the  three  stages  (because  models  were  
fitted  with  the  intercept  suppressed).  These  values  are  identical  to  those  given  in  the  
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‘Rest’  sub-column  of  the  C  (Controls)  column  in  the  corresponding  table  of  means  in  
the  main  text. 
STATE  is  the  estimated  effect  of  the  stress  treatment  on  the  outcome  for control  
subjects,  at  the  baseline  stage. 
INTERACTION  (STAGE  with  STATE)  estimates  the  extent  to  which  the  effect of  the  
stress  treatment  in  controls  at,  respectively,  the  euglycaemic  and hypoglycemic  stages  
varies  relative  to  that  observed  at  the  baseline  stage. 
PRESENCE  OF  DIABETES  estimates  the  difference  in  the  outcome  at  the baseline  
stage,  in  the  resting  state,  between  control  subjects  and  those  with  diabetes.  
INTERACTION  (STAGE  WITH  DIABETES)  estimates  the  extent  to  which  the effect  
of  measurement  stage  (that  is,  the  change  in  resting  values  of  the  outcome  at  the  
euglycemic  and  hypoglycemic  stages  relative  to  the  value observed  at  baseline)  differs  
between  control  subjects  and  those  with  diabetes. 
INTERACTION  (STATE  WITH  DIABETES)  estimates  the extent  to  which  the effect  
of  the  stress  treatment,  at  the  baseline  stage,  differs  between  controls  and  those  with  
diabetes. 
INTERACTION  (STAGE  with  STATE  with  DIABETES)  estimates  the additional  
influence  on  the  outcome  of  the  joint  presence  of  all  main  and  two-way  interaction  
effects.  This  may  be  illustrated  with  reference  to  Table  2b,  from  which  the  predicted 
absolute  value  of  myocardial  blood  volume  under  euglycemia,  post-stress,  in  subjects  
with diabetes  is  given  by:-  
 
 20.4  (main  effect  of  euglycemic  stage) + 
 2.7    (main  effect  of  stress) + 
 0.7    (main  effect  of  diabetes) + 
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 0.7    (euglycemia / stress  interaction) + 
           -0.9    (euglycemia / diabetes  interaction) + 
           -0.4    (stress / diabetes  interaction) = 23.2 
 
However,  the  three-way  interaction  term  indicates  that  the  estimated  value  of the  
outcome  is  0.5  of  a  unit  lower  than  that  which  would  be  predicted  on  the  above  
basis  (though  the  interaction  is  not  statistically  significant).  That  is,  there is  an  
additional  effect  arising  from  the  joint  presence  of  the  euglycemia  stage, the  stress  
state  and  diabetes.  
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Table 1.   
Pulse  rate,  systolic  blood  pressure,  diastolic  blood  pressure  and  rate  pressure  
product at  rest  and  after  dipyridamole-induced  stress during  the hyperinsulinemic  
clamp.  
 
      
Variable Baseline  Hyperinsulinemic 
Euglycemia 
(HE) 
Hyperinsulinemic 
Hypoglycemia 
(HH) 
 C DM C DM C DM 
 
Pulser 
b.min-1 
 
63±9 
 
68±9 
 
66±8 
 
71±14 
 
75±11 
 
78±15 
 
Pulsed 
b.min-1 
 
90±11 
 
92±14 
 
93±14 
 
91±15 
 
97±10 
 
94±14 
 
SBPr 
mmHg 
 
121±14 
 
123±16 
 
124±13 
 
121±15 
 
124±13 
 
120±14 
 
SBPd 
mmHg 
 
125±15 
 
127±18 
 
125±11 
 
120±14 
 
121±11 
 
124±14 
 
DBPr 
mmHg 
 
79±12 
 
73±12 
 
78±9 
 
71±12 
 
69±12 
 
65±9 
 
DBPd 
mmHg 
 
72±9 
 
72±10 
 
71±9 
 
63±11 
 
68±6 
 
62±7 
 
RPPr 
b.min-
1.mmHg 
 
7739± 1533 
 
8394± 1839 
 
8163± 1448 
 
8657± 2114 
 
9454± 1692 
 
9598± 2178 
 
RPPd 
b.min-
1.mmHg 
 
11375± 2399 
 
11705±2399 
 
11533± 1839 
 
10929±2534 
 
11712± 1616 
 
11596±2014 
 
Pulse  rate, systolic  blood  pressure,  diastolic  blood  pressure  and  rate  pressure  product  
are  presented  as  mean±SD. 
C=Healthy controls,  DM=group  with  diabetes  mellitus,  Pulser=resting pulse,  Pulsed=post-
dipyridamole   pulse,  SBPr=resting  systolic  blood  pressure,  SBPd:=post-dipyridamole  
systolic  blood  pressure,  DBPr=resting  diastolic  blood  pressure,  DBPd=post-dipyridamole 
diastolic  blood  pressure,  RPPr= resting  rate  pressure  product,  RPPd= post-dipyridamole 
rate  pressure  product. 
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Table 2:  
 
Effect  of  measurement  stage  and  presence  of  microvascular  complications  on 
myocardial  blood  flow  reserve  (MBFR)  in  subjects  with  diabetes. 
 
variable B coefficient 95% CI p 
INTERCEPT 2.24 2.15 to 2.34 < 0.0001 
MEASUREMENT STAGE: 
euglycaemia vs. baseline 
hypoglycaemia vs. baseline 
 
0.47 
-0.16 
 
0.30 to 0.65 
-0.30 to -0.02 
 
< 0.0001 
0.023 
PRESENCE OF COMPLICATIONS -0.52 -0.70 to -0.34 < 0.0001 
INTERACTION (STAGE with 
COMPLICATIONS): 
euglycaemia and complications present 
hypoglycaemia and complications present 
 
 
 
-0.17 
-0.11 
 
 
 
-0.50 to 0.16 
-0.36 to 0.15 
 
 
0.30 
0.40 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 at SOUTHAMPTON GENERAL HOSPITAL on October 7, 2011http://circ.ahajournals.org/Downloaded from 
10 
 
Table  3.   
 
Endothelin-1,  hs-CRP,  epinephrine,  and  insulin  concentrations  during  the  
hyperinsulinemic  clamp.  
 
 
Variable 
 
Baseline 
 
 
Hyperinsulinemic Euglycemia 
 
 
Hyperinsulinemic Hypoglycemia 
 
Group 
 
0 mins 
 
30 mins 
 
60 mins 
 
90 mins 
 
120 mins 
 
150 mins 
 
180 mins 
 
 
ET-1 
pg.ml-1 
 
C 
 
0.19(1.0) 
 
0.0(0.7) 
 
0.0(0.8) 
 
0.40(0.9) 
 
0.2(0.7) 
 
0.44(0.8) 
 
0.52(0.8) 
 
DM 
 
1.44(0.5) 
 
 
1.30(0.5) 
 
1.32(0.7) 
 
1.49(0.7) 
 
1.44(0.8) 
 
1.45(0.8) 
 
1.49(0.7) 
 
 
hs-CRP  
mg.L-1 
 
C 
 
0.64(0.7) 
 
0.60(0.6) 
 
0.62(0.6) 
 
0.61(0.6) 
 
0.57(0.5) 
 
0.61(0.5) 
 
0.51(0.4) 
 
DM 
 
1.17(1.9) 
 
0.82(1.9) 
 
1.10(1.8) 
 
0.93±1.9 
 
1.10(1.8) 
 
0.9(1.7) 
 
0.82(1.8) 
 
 
Epinep-
hrine 
pg.ml-1 
 
C 
 
76.3±77 
 
77.7±79 
 
91.6±108 
 
96.3±56.7 
 
106.7±84.4 
 
347±199 
 
405.7±310 
 
DM 
 
62.2±44.2 
 
98.3±124.4 
 
86.8±81.9 
 
114.7±93.4 
 
150.7±172 
 
294.8±260.4 
 
350.5±260.4 
 
 
 
Insulin 
pmol.L-1 
 
C 
 
43±23 
 
741±180 
 
728±222 
 
763±160 
 
643±167 
 
683±133 
 
714±160 
 
DM 
 
208.3±207 
 
736.0±227.4 
 
722.6±232.9 
 
663.3±206.7 
 
685.3±209.3 
 
652.9±274.1 
 
647.3±279.7 
 
Values  are  presented  as  median(interquartile  range)  for  ET-1  and  hs-CRP. Values  are  
presented  as  mean±SD  for  epinephrine  and  insulin. 
C=healthy controls, DM=group with diabetes mellitus, ET-1=endothelin-1, hs-CRP= high 
sensitivity CRP, Epinephrine=epinephrine.  
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 Figure  1.  Measurement  of  Myocardial  Blood  Flow  Reserve  using  Flash  Impulse   
 
Imaging. 
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A=myocardial  blood  volume,  βrest=myocardial  blood  velocity  at  rest,   βpeak=myocardial  
blood  velocity  at  peak,  MBFrest=myocardial  blood  flow  at  rest,  MBFpeak=myocardial  
blood  flow  at  peak,  MBFR=myocardial  blood  flow  reserve. 
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